Commercialisation agreement for Ocriplasmin
ThromboGenics NV has entered into an agreement with Alcon for the commercialisation of Ocriplasmin in all markets outside the US. As a result of this deal, ThromboGenics will concentrate on commercialising Ocriplasmin in the US where it plans to build its commercial and medical organisation to support the product’s anticipated launch within the next 12 months.
“Under the terms of the agreement with Alcon, ThromboGenics will receive an up-front payment of €75m. The company is also entitled to a further €90m in potential near-term milestone payments. Additional milestones bring the potential total of up-fronts and milestones to €375m,†said a company spokesman. “In addition, ThromboGenics will receive royalties on net sales of Ocriplasmin that are commensurate with a product that has successfully completed Phase III development and that has been filed for regulatory approval,†he said.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Picture This: Photo Contest Winners
ESCRS 2025 Refractive and Cataract Photo Contest winners.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.